Press Releases

MedImmune and 4D Molecular Therapeutics Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease

July 10, 2018 Emeryville, Ca, USA — MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced ...

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

Emeryville, CA, April 30, 2018 — 4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced the expansion of its 2015 research agreement with F. Hoffmann-La Roche ...

4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for Gene Therapy IND Candidate for Cystic Fibrosis

New Funding Brings Total IND-Enabling Research and Development Support for 4D-710 to over $3.5 Million Emeryville, CA — 4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced $3 million in ...

4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

Emeryville, CA and Columbia, MD | July 24, 2017 — 4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding ...

4D Molecular Therapeutics Enrolls First Patient in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | December 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in gene therapy product discovery and development, today announced the enrollment of the first participant in its ...

4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia

Intravitreal delivery to the retina is critical to Choroideremia treatment Emeryville, CA | February 23, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, and the Choroideremia Research Foundation (CRF), a ...

4D Molecular Therapeutics Announces Collaboration with Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development

Leader in proprietary gene therapy vector discovery closes fifth partnership Emeryville, CA, Jan 7, 2016 — 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and ...

Johnson & Johnson Innovation Announces Opening of the California Innovation Center

MENLO PARK, Calif. (June 5, 2013) – Johnson & Johnson Innovation today announced the opening of the Johnson & Johnson California Innovation Center, one of four regional hubs being established in the world’s leading life science innovation hotspots. A part ...